Xvivo Perfusion AB (CHIX:XVIVOS) Net Change in Cash : kr-144.3 Mil (TTM As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Xvivo Perfusion AB Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Xvivo Perfusion AB's Net Change in Cash for the three months ended in Sep. 2024 was kr-30.8 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2024 was kr-144.3 Mil.

Xvivo Perfusion AB Net Change in Cash Historical Data

The historical data trend for Xvivo Perfusion AB's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xvivo Perfusion AB Net Change in Cash Chart

Xvivo Perfusion AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Change in Cash

Get a 7-Day Free Trial

-27.12

194.29

44.46

-152.15

299.54

Xvivo Perfusion AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Net Change in Cash	Get a 7-Day Free Trial															422.82	-48.17	-34.94	-30.39	-30.79

Xvivo Perfusion AB Net Change in Cash Calculation

Xvivo Perfusion AB's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	46.287	+	-161.619	+	418.547	+	-3.672
	=	299.5

Xvivo Perfusion AB's Net Change in Cash for the quarter that ended in Sep. 2024

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= 22.876 + -41.484 + -2.618 + -9.56

= -30.8

Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-144.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xvivo Perfusion AB Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Xvivo Perfusion AB's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Xvivo Perfusion AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xvivo Perfusion AB (CHIX:XVIVOs) » Definitions » Net Change in Cash

Comparable Companies

OSTO:MCAP OSTO:EKTA B OSTO:CEVI OSTO:BICO OSTO:SEDANA OSTO:BACTI B OSTO:PAX OSTO:VITR OSTO:CRAD B OSTO:OSSD ABT SYK BSX MDT XTER:SHL EW SZSE:300760 DXCM XAMS:PHIA ZBH

Traded in Other Exchanges

XVIPF:USA XVIVO:Sweden 0RKL:UK 3XV:Germany

Address

Gemenskapens gata 9, Molndal, SWE, SE-431 53

Website

https://www.xvivoperfusion.com

Xvivo Perfusion AB is a medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments namely, Thoracic: Sales of lung and heart transplant products, Abdominal: Sales of liver and kidney transplant products. Services: Revenue from sales of services in organ recovery (carried out by subsidiary STAR Teams Inc.). The majority of revenue is derived from the Thoracic segment. Geographically, the majority is from the United States.

Xvivo Perfusion AB Headlines

No Headlines